🔍 Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI and the Pharmaceutical Industry — 2026-09-22 (Tue)

Daily ReportPast 24h · aggregated 06:20 JST·13 items

This section covers corporate investment behaviour of pharmaceutical companies, not the efficacy or safety of any medicinal product. Headlines are quoted as published; no claim about product performance is made or implied by this site. Collection and classification are automated and may misclassify or miss items. Disclaimer

Harvested 442Accepted 13Stale 97Duplicate 93Low-quality source 14Market noise 7Market research 4Off-topic 185No investment signal 29
💰 Investment MapAmounts are extracted from source text by pattern matching only. No currency conversion.
AmountDealFunctionSource
$400MAnthropic's $400M Buy Gives New York's Life Sciences' AI Sector a Boost🏛️ Enterprise AI Platform & GovernanceGlobest
Korea's NAVER D2SF invests in AI-driven precision medicine company ImpriMed🏛️ Enterprise AI Platform & GovernanceBioSpectrum Asia
🧬 Drug Discovery7
🧪 Clinical Development0
No items today · See past 90 days →
📑 CTD / Regulatory Submission0
No items today · See past 90 days →
🩺 GCP Operations0
No items today · See past 90 days →
📘 ICH Guidelines & AI0
No items today · See past 90 days →
🛡️ Pharmacovigilance / GVP0
No items today · See past 90 days →
📊 RWE / Evidence Generation0
No items today · See past 90 days →
🎓 Medical Affairs0
No items today · See past 90 days →
💼 Sales0
No items today · See past 90 days →
📣 Marketing0
No items today · See past 90 days →
🚚 Distribution / Supply Chain0
No items today · See past 90 days →
GQP / Quality Assurance0
No items today · See past 90 days →
👥 Human Resources0
No items today · See past 90 days →
💴 Finance & Accounting0
No items today · See past 90 days →
🏛️ Enterprise AI Platform & Governance6
← 2026-09-21Index
← AI and the Pharmaceutical Industry — index